Determining Clinicopathologic Factors That Influence Treatment in Advanced Breast Cancer in Argentina After CDK4/6 Inhibitors
In our study, treatment decisions reflected the current algorithm incorporated in our clinical guidelines, and prior treatment response was the most relevant factor to determine 2L treatment decision. Menopausal status interacted with the subsequent therapy efficacy in this setting. Hence, we consider that menopausal status should be routinely evaluated in the subgroup analysis of clinical trials.
Authors
- Carolina Almada
- R. Villarreal Gonzalez
- A. Guercovich
- A. Mainella
- Maribel A. Lutteral
- Gonzalo Gomez-Abuin
- Luciano Cermignani
- Natalia Ayala
- Cristian Micheri
- M.C. Riggi (ORCID: https://orcid.org/0000-0001-6235-9527)
- Melina Winocur
- Ana Carolina Ituarte
- Federico Waisberg (ORCID: https://orcid.org/0000-0003-4435-5068)
- Rosa Penayo
- A Mazzotta (ORCID: https://orcid.org/0000-0002-2432-1576)
- Pablo Mandó (ORCID: https://orcid.org/0000-0001-8387-9011)
- M.L. Casalnuovo
- S. Cinquini
- Janeth Lara Alcántara (ORCID: https://orcid.org/0009-0005-6598-0227)
- Pamela Llugdar
- Naima Kassis
- L. Gonzalez Mattos
Institutions
- Hospital Italiano de Buenos Aires (AR)
- Instituto Alexander Fleming (AR)
- Instituto Oncológico de Córdoba (AR)
- Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno (AR)
- Hospital Alemán (AR)
- Hospital Británico de Buenos Aires (AR)
- Instituto de Oncología de Rosario (AR)
- Hospital General de Agudos Dr. TEODORO ALVAREZ (AR)
Publication Details
- Journal
- JCO Global Oncology
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1200/go.24.00056
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00